Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson’s disease (PD)

Background: Glial neutrophic factor (GDNF) is a random fact of a trophic neuron, especially dopaminergic neurons.

Method: We examined 78 patients with PD aged 18 to 70 years (mean age 56.04±8.7), including 39 men and 39 women. The control group of patients included 12 patients without PD, who matched in age and sex. The duration of the disease was 4.1±5.6 years. All patients with clinical-neurological, neurophysiological and allergenic studies from patients with secondary brain diseases. GDNF levels were determined by enzyme immunoassay.

Results: The results of measurements were obtained that in the blood serum of patients of the main group, the amount of glial neurotic inflammation was 34.655±7.5 pg/ml, in the control group 73.558±8.2 pg/ml, (p<0.05). In the main content of the GDNF group, it was two times lower than in the control group. In patients with initial manifestations of PD, the GDNF level was 45.9±4.8 pg/ml, while in patients with a disease duration of 2-4 years, the GDNF level was 29.6±3.02 pg/ml, (p<0.05). A decrease for GDNF in the blood serum in patients with PD is associated with trophic of dopaminergic neurons in disorders of the pallidar system that occur in astrocytes cells.

Conclusion: Thus, based on the data obtained, it can be concluded that glial neurotrophic factor may be an early diagnostic marker of Parkinson’s disease.

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/glial-neurotrophic-factor-as-an-early-diagnostic-marker-in-parkinsons-disease/